SmallCaps
ASX:TRIHealth Care Equipment & ServicesHealth Care Technology

TrivarX Ltd

$0.016
+$0.001 (+6.67%)
Day Range
$0.016 – $0.016
52 Week Range
$0.009 – $0.035
Volume
224.27K
Avg Volume (10D)
336.95K
Market Cap
$18.46M

Price Chart

OHLC · volume · moving averages

$0.016-$0.012 (-42.86%)over 6M
Hi$0.032Lo$0.014
Price-sensitive newsVolumePrev close · 52W range

Market Statistics

Today's trading range

Open
$0.016
Previous Close
$0.015
Day High
$0.016
Day Low
$0.016
52 Week High
$0.035
52 Week Low
$0.009

Valuation

Fundamental multiples

Market Cap
18.46M
Shares Outstanding
1.15B
Price to Book
0.73

Trading Activity

Volume & order book

Volume
224.27K
Value Traded
3.59K
Bid
$0.016 × 32,136
Ask
$0.017 × 364,949

Performance

Returns across timeframes

1 Day
0.00%
5 Day
7.14%
13 Week
-48.28%
52 Week
50.00%
YTD
-21.05%

Technical Indicators

Momentum & moving averages

RSI (14)
49.40
50-Day SMA
$0.018
200-Day SMA
$0.021

— From the desk

Latest News

TrivarX to Acquire Stabl-Im Diagnostic Technology for Early Detection of Metastatic Brain Tumours
Biotechnology

TrivarX to Acquire Stabl-Im Diagnostic Technology for Early Detection of Metastatic Brain Tumours

TrivarX (ASX: TRI) has announced plans to acquire novel Stabl-Im metastatic brain technology and associated stable isotope cancer diagnostic intellectual property from Australian company Nucleics. Stabl-Im represents a potential breakthrough in the safe and non-invasive detection of brain cancers and metastases using standard magnetic resonance imaging (MRI) equipment to visualise and monitor tumour growth without the […]

TrivarX R&D program advances MEB-001 algorithm for screening of depressive episodes
Biotechnology

TrivarX R&D program advances MEB-001 algorithm for screening of depressive episodes

An extensive research and development (R&D) program by mental health technology company TrivarX (ASX: TRI) has advanced the company’s proprietary artificial intelligence-backed algorithm MEB-001 for the screening of current major depressive episode (cMDE). The algorithm can accurately conduct sleep staging and screen for cMDE in subjects through a single-channel electrocardiogram, using heart rate and heart […]

TrivarX completes Phase 2 MEB-001 algorithm sleep study for depressive episodes
Biotechnology

TrivarX completes Phase 2 MEB-001 algorithm sleep study for depressive episodes

Medical health technology company TrivarX (ASX: TRI) has completed a Phase 2 sleep signal analysis for current major depressive episode (SAMDE) study utilising its proprietary artificial intelligence-backed algorithm MEB-001. The study aimed to validate MEB-001 in the screening and diagnosis of current major depressive episodes in 400 participants enrolled at 15 sleep centres across the […]